88 results
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
decreasing the number of patients who are required to dose-adjust or discontinue treatment because of side effects or lack of response.
Our Strategy …
Our strategy is to develop our pipeline of NGC proprietary small molecule oncology drugs using our regulatory science approach to determine
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
the FDA — have allowed us to develop a Phase 2 and 3 strategy that will likely be more efficient in terms of time and cost as well as lead to a greater
8-K
EX-99.1
vyclv
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
8-K
EX-99.1
kgvo2 9yd
8 Aug 23
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
10:30am